Explain this page
Arphra AIPlain-English read on Citius Oncology, Inc.’s valuationBusiness description
· company · SEC profileCitius Oncology, Inc.
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Founded
—
IPO
Dec 08, 2022
Employees
285
HQ
New York City, NY
CEO
Leonard L. Mazur
CFO
—
Exchange
NASDAQ
Fiscal year
—
Identifiers
· company_identifiersCIK0001851484
CUSIP17331Y109
ISINUS17331Y1091
FIGICTOR US
LEI—